@Hasli1987. Saya rasa yang dirujuk melibatkan vaksin dikaitkan dengan YongTai. Untuk tujuan trial 3. Di Malaysia juga akan dibuat trial bersama-sama dengan dari beberapa negara lain. -------------------------------- Kenyataan Akhbar KPK 5 Jun 2021 – Kajian Klinikal Produk SARS-CoV-2 Vaccine (Vero Cells), Inactivated Keluaran Shenzhen Kangtai Biological Products Co., Ltd., China
Kementerian Kesihatan Malaysia (KKM) ingin memaklumkan bahawa terdapat tambahan satu (1) kajian klinikal yang melibatkan vaksin COVID-19 telah diluluskan oleh Bahagian Regulatori Farmasi Negara (NPRA) pada 28 Mei 2021. Kajian klinikal ini melibatkan produk SARS-CoV-2 Vaccine (Vero Cells), Inactivated, 5μg/0.5mL yang dikilangkan oleh pengilang Shenzhen Kangtai Biological Products Co., Ltd. di negara China.
Kajian Klinikal Fasa 3 ini akan dijalankan di lapan (8) pusat penyelidikan di Malaysia dengan sasaran peserta sebanyak 3,000 orang dewasa yang berumur 18 tahun dan ke atas serta dijangka akan mengambil masa selama 15 hingga 19 bulan. Malaysia merupakan salah sebuah negara yang terlibat dalam kajian klinikal ini selain daripada Colombia, Argentina, Pakistan, Filipina dan Ukraine. Vaksin ini juga telah diluluskan oleh negara China melalui Emergency Use Approval pada 14 Mei 2021.
KUALA LUMPUR: Private hospitals will likely get their vaccine supplies earliest by September or October this year and only after obtaining Health Ministry's National Pharmaceutical Regulatory Agency (NPRA) approval.
Association of Private Hospital of Malaysia (APHM) president Datuk Dr Kuljit Singh said these vaccines, different from the existing ones, might take between two and three months in a best-case scenario for private hospitals to procure on the condition that the government hasten their vaccines approval.
Dr Kuljit said private hospitals could not source vaccines like Pfizer and AstraZeneca that the government has already procured.
"Hence, we have to look at procuring Moderna, Johnson and Johnson and Sinopharm. These vaccines have yet to register with NPRA. We need to apply these vaccines and get approval from NPRA," he told the New Straits Times when contacted yesterday.
Sedikit maklumat boleh dirujuk berkaitan kelulusan vaksin Sinopharm di peringkat WHO dan teori berkaitan status permohonan kelulusan NPRA vaksin Sinopharm tersebut yang ada kaitan dengan Kanger. -------------------------------
Article: Is It True That The Process of Registering The Sinopharm Vaccine (With NPRA) Has Started?
MZM2511 @Hasli1987. Saya rasa yang dirujuk melibatkan vaksin dikaitkan dengan YongTai. Untuk tujuan trial 3. Di Malaysia juga akan dibuat trial bersama-sama dengan dari beberapa negara lain...
maknanya bukan vaksn Sinopharm lah yg disebut oleh DG Hisham tu?...
KJ sahkan ada pihak tempatan cuba daftar vaksin Sinopharm
Menteri Penyelaras Program Imunisasi COVID-19 Kebangsaan sahkan terdapat beberapa pihak tempatan yang sedang cuba mendaftarkan vaksin Sinopharm dihasilkan syarikat farmaseutikal dari China. Vaksin sinopharm tidak termasuk di dalam Program Imunisasi COVID-19 Kebangsaan (PICK). Kata Khairy Jamaluddin, perkara berkenaan adalah dibenarkan dan pihaknya mengalu-alukan perkara tersebut. (May 21, 2021)
badan kesihatan dunia tidak menggalakan penggunaan Ivermectin kerena bimbang akan berlaku masalah lain dalam system badan manusia kerana ia nya lebih kepada membunuh parasite dalam tubuh haiwan bukan virus corona.
sebelum malaysia mencuba Ivermectin, badan kesihatan dunia sudah pon cuba dan hasill nya tidak memberangsangkan.
Right issue 1:1 where o 2,861,936,149 RI and later will join the mother then the total share (exclude warrants) would be 5,723,872,298 shares will be floating in market. Later, subject to time, another 2,861,936,149 Warrant upon exercise will also join in. Woah... I can't imagine how much quantity going to be there in the market. I do not really understand how this share can fly with so many volumes in the market. Can somebody digest it for me
For Example; MY E.G has a NOSH of 3.777 million and @ RM1.96. MY E.G was proposed to add another 4.149 million Bonus Shares via its 1:1 Bonus Share. From the next PP exercise, up to 220 million new share will added. What a big NOSH MY E.G. will has then..
Note: May be we can't compare between "a Scam company" with "a non scam company". He He
Hi, just dropping by to remind ppl that it's not true after receiving two doses of vaccines then you are done for life..... still need booster shots!.....after as short as 6 months?
we believe in kanger, coz till now it a mostly close counter to get sinopharm vaccine, and maybe inix had propose b4, but never get any progress even from china or local.. so other counter yes, yong tai but still no any plan to distribute... only for 3rd trial.. so which u choose?? ucrest for spuntik V, with most of world still not accept it... just see how this vaccine drama can go untill how far...
Kelulusan WHO tingkatkan keyakinan terhadap vaksin Sinovac - Khairy (2 Jun 2021)
Kelulusan Pertubuhan Kesihatan Sedunia (WHO) terhadap vaksin COVID-19 Sinovac akan meningkatkan keyakinan terhadap pengambilan vaksin tersebut.
Menurut Menteri Penyelaras Program Imunisasi Covid-19 Kebangsaan (PICK) Khairy Jamaluddin Abu Bakar, ini membuktikan vaksin tersebut selamat dan berkesan.
KUALA LUMPUR: Kelulusan Pertubuhan Kesihatan Sedunia (WHO) terhadap vaksin COVID-19 Sinovac akan meningkatkan keyakinan terhadap pengambilan vaksin tersebut. Menurut Menteri Penyelaras Program Imunisasi Covid-19 Kebangsaan (PICK) Khairy Jamaluddin Abu Bakar, ini membuktikan vaksin tersebut selamat dan berkesan. "Pengiktirafan global ini meningkatkan keyakinan ketika 12 juta bekalan vaksin Sinovac kita akan memastikan 18 peratus populasi negara ini mendapat manfaat daripadanya," katanya menerusi akaun Twitter hari ini.
Terdahulu hari ini, WHO meluluskan vaksin COVID-19 keluaran Sinovac itu untuk kegunaan kecemasan iaitu vaksin kedua buatan China yang menerima kelulusan itu. Agensi kesihatan Pertubuhan Bangsa-Bangsa Bersatu (PBB) itu sudah memuktamadkan kelulusan vaksin dua dos itu, yang kini sudah diedarkan ke beberapa negara di serata dunia. Bulan lalu(Mei), Sinopharm menjadi vaksin COVID-19 pertama buatan China yang mendapat kelulusan WHO.
Selain itu, turut mendapat kelulusan WHO untuk penggunaan kecemasan ialah vaksin Pfizer/BioNTech, Moderna, Johnson & Johnson dan AstraZeneca yang dihasilkan di India, Korea Selatan dan Kesatuan Eropah (EU).
Because under table haven gaodim yet… same with Sinovac. So many country using but until dunno pun don’t let pharmaniaga to produce cz without NPRA approve. once gaodim under table talk and finally allow pharmaniaga to bottling and filling.
2obakh122. ------------------ 1. The current Kanger's Bamboo Floring and related product businesses
Kanger (017) is a "green" building materials provider, specialising in the manufacturing and trading of bamboo flooring and related products for the residential and commercial markets under its brands 'Kanger' and 'KAR Masterpiece' as well as OEM at the request of its customers. In additional, it also sell strand woven bamboo planks, a semi-finished product from its strand woven bamboo flooring manufacturing process, to furniture and building materials manufacturers as raw materials for their production. The bamboo flooring and related products business is still running well as can be seen at these websites:
On September 2020, Kanger planned to strengthen their bamboo products business. Kanger is on target to become the world’s largest producer of bamboo products with the commencement of a new high-tech bamboo processing plant and R&D centre, which was developed in collaboration with the local government of Jingzhou, Hunan Province, China. Kanger has accumulated vast experience and strong know-how of the bamboo industry, having been involved in the bamboo processing business over the past 16 years.
2 Kanger are in the process of exploring new businesses:
A. To secure as a distributor of Sinopharm Covid-19 vaccines in Malaysia.
B. To be involved in the sales and trading of building materials, which include, timber flooring, tiles, bulk cement, concrete, locksets and sanitary ware by acquiring 51% equity interest in Sung Master.
Estimates suggest that with an average of 60,433 doses administered daily, Indonesia would take over 10 years to vaccinate 75 per cent of its population.
The slow progress of COVID-19 vaccination in Indonesia can be put down to limited global vaccine supply, the unpreparedness of the national health system and vaccine hesitancy.
The global capacity to manufacture vaccines remains limited: To cover 70 per cent of the global population, at least 11 billion doses are required. This need simply cannot be met by the manufacturers immediately.
High-income countries have acquired 77 per cent of Pfizer’s, 27 per cent of AstraZeneca’s and 18 per cent of Sinovac’s 2021 COVID-19 vaccine production capacity.
WHO lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations
7 May 2021 News release Reading time: 3 min (917 words)
WHO today listed the Sinopharm COVID-19 vaccine for emergency use, giving the green light for this vaccine to be rolled out globally. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG).
Post a Comment
People who like this
New Topic
You should check in on some of those fields below.
Title
Category
Comment
Confirmation
Click Confirm to delete this Forum Thread and all the associated comments.
Report Abuse
Please Sign In to report this post as abuse.
Market Buzz
No result.
Featured Posts
MQ Trader
Introducing MY's First IPO Fund for Sophisticated Investors!
MQ Chat
New Update. Discover investment communities that resonate with your ideas
MQ Trader
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
0:17
New IPO: O&G healthcare service provider, Metro Healthcare Berhad aims to list on the Ace Market!
MQ Trader 174 views | 1 d ago
0:17
New IPO: Life Water Berhad, a manufacturer of drinking water and carbonated beverages, aims to list on the Main Market!
MQ Trader 1114 views | 2 d ago
0:17
New IPO: Mega Fortris Berhad, a manufacturer of security seals, aims to list on the Main Market!
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
MZM2511
4,548 posts
Posted by MZM2511 > 2021-06-05 18:04 | Report Abuse
@Hasli1987. Saya rasa yang dirujuk melibatkan vaksin dikaitkan dengan YongTai. Untuk tujuan trial 3. Di Malaysia juga akan dibuat trial bersama-sama dengan dari beberapa negara lain.
--------------------------------
Kenyataan Akhbar KPK 5 Jun 2021 – Kajian Klinikal Produk SARS-CoV-2 Vaccine (Vero Cells), Inactivated Keluaran Shenzhen Kangtai Biological Products Co., Ltd., China
Kementerian Kesihatan Malaysia (KKM) ingin memaklumkan bahawa terdapat tambahan satu (1) kajian klinikal yang melibatkan vaksin COVID-19 telah diluluskan oleh Bahagian Regulatori Farmasi Negara (NPRA) pada 28 Mei 2021. Kajian klinikal ini melibatkan produk SARS-CoV-2 Vaccine (Vero Cells), Inactivated, 5μg/0.5mL yang dikilangkan oleh pengilang Shenzhen Kangtai Biological Products Co., Ltd. di negara China.
Kajian Klinikal Fasa 3 ini akan dijalankan di lapan (8) pusat penyelidikan di Malaysia dengan sasaran peserta sebanyak 3,000 orang dewasa yang berumur 18 tahun dan ke atas serta dijangka akan mengambil masa selama 15 hingga 19 bulan. Malaysia merupakan salah sebuah negara yang terlibat dalam kajian klinikal ini selain daripada Colombia, Argentina, Pakistan, Filipina dan Ukraine. Vaksin ini juga telah diluluskan oleh negara China melalui Emergency Use Approval pada 14 Mei 2021.